Your browser doesn't support javascript.
loading
Proteomic signatures for identification of impaired glucose tolerance.
Carrasco-Zanini, Julia; Pietzner, Maik; Lindbohm, Joni V; Wheeler, Eleanor; Oerton, Erin; Kerrison, Nicola; Simpson, Missy; Westacott, Matthew; Drolet, Dan; Kivimaki, Mika; Ostroff, Rachel; Williams, Stephen A; Wareham, Nicholas J; Langenberg, Claudia.
Affiliation
  • Carrasco-Zanini J; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Pietzner M; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Lindbohm JV; Computational Medicine, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Wheeler E; Clinicum, Department of Public Health, University of Helsinki, Helsinki, Finland.
  • Oerton E; Department of Epidemiology and Public Health, University College London, London, UK.
  • Kerrison N; The Klarman Cell Observatory, Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
  • Simpson M; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Westacott M; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Drolet D; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Kivimaki M; SomaLogic, Inc., Boulder, CO, USA.
  • Ostroff R; SomaLogic, Inc., Boulder, CO, USA.
  • Williams SA; SomaLogic, Inc., Boulder, CO, USA.
  • Wareham NJ; Clinicum, Department of Public Health, University of Helsinki, Helsinki, Finland.
  • Langenberg C; Department of Epidemiology and Public Health, University College London, London, UK.
Nat Med ; 28(11): 2293-2300, 2022 11.
Article in En | MEDLINE | ID: mdl-36357677
ABSTRACT
The implementation of recommendations for type 2 diabetes (T2D) screening and diagnosis focuses on the measurement of glycated hemoglobin (HbA1c) and fasting glucose. This approach leaves a large number of individuals with isolated impaired glucose tolerance (iIGT), who are only detectable through oral glucose tolerance tests (OGTTs), at risk of diabetes and its severe complications. We applied machine learning to the proteomic profiles of a single fasted sample from 11,546 participants of the Fenland study to test discrimination of iIGT defined using the gold-standard OGTTs. We observed significantly improved discriminative performance by adding only three proteins (RTN4R, CBPM and GHR) to the best clinical model (AUROC = 0.80 (95% confidence interval 0.79-0.86), P = 0.004), which we validated in an external cohort. Increased plasma levels of these candidate proteins were associated with an increased risk for future T2D in an independent cohort and were also increased in individuals genetically susceptible to impaired glucose homeostasis and T2D. Assessment of a limited number of proteins can identify individuals likely to be missed by current diagnostic strategies and at high risk of T2D and its complications.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glucose Intolerance / Diabetes Mellitus, Type 2 Type of study: Diagnostic_studies / Guideline / Prognostic_studies Limits: Humans Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2022 Document type: Article Affiliation country: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glucose Intolerance / Diabetes Mellitus, Type 2 Type of study: Diagnostic_studies / Guideline / Prognostic_studies Limits: Humans Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2022 Document type: Article Affiliation country: Reino Unido